Atrial Fibrillation (AF) stands as a common cardiac rhythm disorder marked by irregular and frequently accelerated heartbeats. This condition arises when the heart's upper chambers (atria) undergo a quivering or fluttering motion, disrupting the normal electrical impulses that coordinate heartbeats. Consequently, the heart may struggle to efficiently pump blood, potentially leading to complications like blood clots, strokes, or heart failure. Although AF can affect individuals of various age groups, its prevalence tends to increase with age, with factors such as hypertension, diabetes, and heart disease heightening the risk. Recognizable symptoms encompass palpitations, fatigue, dizziness, and shortness of breath. The timely identification and effective management of Atrial Fibrillation are pivotal in reducing associated risks and improving the quality of life for those impacted. Treatment approaches typically include medications, lifestyle adjustments, and, in specific cases, medical procedures designed to restore or regulate the heart's rhythm. Ongoing research efforts contribute to a growing understanding of AF mechanisms, offering promise for innovative treatment options and advancements in patient care.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States